公开(公告)号：US20060165036A1

公开(公告)日：2006-07-27

申请号：US11236895

申请日：2005-09-28

申请人： Arty Chandra ,  Sudheer Grandhi ,  Eldad Zeira ,  Joseph Levy ,  Sintayehu Dehnie ,  Mohammed Sammour

发明人： Arty Chandra ,  Sudheer Grandhi ,  Eldad Zeira ,  Joseph Levy ,  Sintayehu Dehnie ,  Mohammed Sammour

IPC分类号： H04Q7/00 ,  H04L12/56

CPC分类号： H04W74/08 ,  H04L47/26 ,  H04L47/30 ,  H04W74/002 ,  Y02D70/142 ,  Y02D70/22

摘要： A method and system for eliminating interference caused by hidden nodes is disclosed. An initiator control message is defined for an initiator, (typically a wireless station (STA)), in order to begin an aggregate frame exchange with at least one responder. The initiator control message includes information on the queue sizes at the initiator. A responder, (typically an access point (AP)), sets up the required protection for the transmission of data by the initiator based on information on the queue sizes indicated in a field of the initiator control message using a responder control message. Other STAs that receive the responder control message set parameters for a wireless medium access accordingly. In another embodiment, multiple receiver aggregate multi-poll (MMP) and power save aggregation descriptor (PSAD) control frames are configured for transmission by a non-AP STA to provide enhanced scheduling and mitigate hidden node problems.

摘要翻译： 公开了一种消除隐藏节点干扰的方法和系统。 为启动器（通常为无线站（STA））定义发起者控制消息，以开始与至少一个响应者的聚合帧交换。 启动器控制消息包括关于发起者的队列大小的信息。 响应者（通常为接入点（AP）），基于使用响应者控制消息的发起者控制消息的字段中指示的队列大小的信息，建立由发起者传输数据所需的保护。 接收响应者控制消息的其他STA相应地为无线介质访问参数。 在另一个实施例中，多个接收机集合多轮询（MMP）和功率节省聚合描述符（PSAD）控制帧被配置为由非AP STA传输，以提供增强的调度并减轻隐藏的节点问题。

公开(公告)号：US4252745A

公开(公告)日：1981-02-24

申请号：US92384

申请日：1979-11-08

申请人： Gary Kwong ,  Joseph Levy

发明人： Gary Kwong ,  Joseph Levy

IPC分类号： C10L1/222 ,  C10M149/14 ,  C07C89/02

CPC分类号： C10M133/08 ,  C10L1/2225 ,  C10M149/14 ,  C10M2215/042 ,  C10M2217/041 ,  C10N2230/04 ,  C10N2230/06 ,  C10N2230/12

摘要： Novel compositions comprise the polymeric reaction products of primary alkoxyalkylamines with epihalohydrins at temperatures in the range from about 40.degree. C. to about 150.degree. C. in the presence of an inorganic base. Such reaction products may be used as sedimentation and degradation inhibitors in hydrocarbon oils, antifoulants, carburetor detergents, lubricant additives, and corrosion inhibitors.

摘要翻译： 新型组合物包含在无机碱存在下，在约40℃至约150℃的温度范围内的伯烷氧基烷基胺与表卤代醇的聚合反应产物。 这种反应产物可用作烃油，防污剂，化油器清洁剂，润滑剂添加剂和腐蚀抑制剂中的沉降和降解抑制剂。

公开(公告)号：US4152529A

公开(公告)日：1979-05-01

申请号：US851901

申请日：1977-11-16

申请人： Nils J. Christensen ,  Joseph Levy

发明人： Nils J. Christensen ,  Joseph Levy

IPC分类号： C07C37/50 ,  C07C39/24

CPC分类号： C07C37/50 ,  Y02P20/582

摘要： Halogenated alkyl substituted phenols may be dealkylated by treating a compound such as 5-t-butyl-2-fluorophenol with a diealkylation catalyst such as an acid acting compound at dealkylation conditions whereby the t-butyl substituent is removed and the resulting compound comprising 2-fluorophenol is recovered.

摘要翻译： 卤烷基取代的苯酚可以通过在脱烷基化条件下用烷基化催化剂如酸作用化合物处理化合物如5-叔丁基-2-氟苯酚而脱烷基化，由此除去叔丁基取代基，所得化合物包含2- 回收氟苯酚。

公开(公告)号：US20150275302A1

公开(公告)日：2015-10-01

申请号：US14674606

申请日：2015-03-31

申请人： Mario Masellis ,  Joanne Knight ,  Maureen Shannon Collinson ,  Anthony Edward Lang ,  James Lowery Kennedy ,  Joseph Levy ,  Amir Tchelet ,  Iris Grossman ,  Eli Eyal ,  Ofra Barnett

发明人： Mario Masellis ,  Joanne Knight ,  Maureen Shannon Collinson ,  Anthony Edward Lang ,  James Lowery Kennedy ,  Joseph Levy ,  Amir Tchelet ,  Iris Grossman ,  Eli Eyal ,  Ofra Barnett

IPC分类号： C12Q1/68 ,  A61K45/06 ,  A61K31/4985 ,  A61K31/48 ,  A61K31/198 ,  A61K31/4045 ,  A61K31/428 ,  A61K31/381 ,  A61K31/135 ,  A61K31/439

CPC分类号： C12Q1/6883 ,  A61K31/135 ,  A61K31/198 ,  A61K31/381 ,  A61K31/4045 ,  A61K31/428 ,  A61K31/439 ,  A61K31/48 ,  A61K31/4985 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

摘要： This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline.

摘要翻译： 本申请提供了用药物组合物治疗患有帕金森病（PD）的人类受试者的方法，所述药物组合物包含雷沙吉兰或雷沙吉兰的药学上可接受的盐和药学上可接受的载体，包括以下步骤：（i）获得包含 来自人类受试者患有帕金森病的基因组; （ii）使用探针或引物从人受试者测定生物样品的DNA或RNA，以确定单核苷酸多态性（SNP）rs1076560或rs2283265处人受试者的二倍体基因型; （iii）如果二倍体基因型是rs1076560的CC，rs2283265的CC或rs1076560和rs2283265的CC，则将人受试者鉴定为雷沙吉兰的预测应答者; 和（iv）如果人类受试者被鉴定为雷沙吉兰的预测应答者，则向人类受试者施用包含雷沙吉兰和药学上可接受的载体的药物组合物。

公开(公告)号：US20150045306A1

公开(公告)日：2015-02-12

申请号：US14467954

申请日：2014-08-25

申请人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

发明人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

IPC分类号： C12Q1/68 ,  A61K45/06 ,  A61K38/16

CPC分类号： C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156

摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

摘要翻译： 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测 通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

公开(公告)号：US20080096602A1

公开(公告)日：2008-04-24

申请号：US11959578

申请日：2007-12-19

申请人： Stephen Terry ,  Robert DiFazio ,  Stephen Dick ,  Joseph Levy

发明人： Stephen Terry ,  Robert DiFazio ,  Stephen Dick ,  Joseph Levy

IPC分类号： H04B7/00

CPC分类号： H04W52/30 ,  H04W52/223 ,  H04W52/262 ,  H04W52/367 ,  H04W52/50

摘要： The present invention discloses a method and system for enabling efficient reduction of TFCs in the TFCS to achieve desired transmission, while remaining within desired power and data requirements. Upon the UE transmission power requirement exceeding the maximum or allowable transmission power the MAC shall be informed for subsequent TFC selection of all TFCs that currently exceed this limit. The UE will then chose the TFC with the next lower transmission power requirement and the sequence will continue until an acceptable TFC is determined. The present invention also enables the replacement of the TFCs in the TFCS and advanced determination of non-supported TFCS. The TFCs that require transmission power greater then the maximum or allowed UE transmission power shall be determined continuously in every TTI, not just in TTIs where the maximum power has been exceeded.

摘要翻译： 本发明公开了一种能够有效地降低TFCS中的TFC以实现期望的传输并保持在期望的功率和数据要求内的方法和系统。 在UE发射功率要求超过最大或允许的发射功率时，MAC将被通知用于当前超过该限制的所有TFC的后续TFC选择。 然后，UE将选择具有下一个较低传输功率要求的TFC，并且该序列将继续，直到确定可接受的TFC为止。 本发明还能够更换TFCS中的TFC并且进一步确定不支持的TFC。 要求传输功率大于最大或允许的UE传输功率的TFC应在每个TTI中连续地确定，而不仅仅是在超过最大功率的TTI中。

公开(公告)号：US20070171858A1

公开(公告)日：2007-07-26

申请号：US11618328

申请日：2006-12-29

申请人： Sudheer Grandhi ,  Mohammed Sammour ,  Joseph Levy

发明人： Sudheer Grandhi ,  Mohammed Sammour ,  Joseph Levy

IPC分类号： H04Q7/00

CPC分类号： H04W72/1278 ,  H04W74/002 ,  H04W74/0833 ,  H04W84/12 ,  Y02D70/142 ,  Y02D70/144 ,  Y02D70/22

摘要： A method and system applies MAC transmission opportunity (TXOP) protection for multiple mode operation in a WLAN system. In particular, MAC mechanisms are defined to support multiple mode CTS frames, and multiple mode CF-End frames sent by the AP, each in a format appropriate for the corresponding mode which also applies to a single mode as a trivial case. MAC mechanisms permit truncation of TXOP duration for releasing the unused portion of the TXOP when no further data for transmission is available. Release of unused protected TXOP is possible for both protected AP transmissions and STA transmissions.

摘要翻译： 一种方法和系统在WLAN系统中对多模式操作应用MAC传输机会（TXOP）保护。 特别地，MAC机制被定义为支持多模式CTS帧，以及由AP发送的多模式CF-结束帧，每个帧的格式适合于对应的模式，其也适用于单个模式作为平凡的情况。 当没有进一步的传输数据可用时，MAC机制允许截断TXOP持续时间以释放TXOP的未使用部分。 对于受保护的AP传输和STA传输都可以释放未使用的受保护的TXOP。

公开(公告)号：US6163564A

公开(公告)日：2000-12-19

申请号：US132037

申请日：1998-08-11

申请人： Ronald Rudish ,  Joseph Levy

发明人： Ronald Rudish ,  Joseph Levy

IPC分类号： G01S13/02 ,  G01S13/28 ,  G01S13/32 ,  H01Q3/26 ,  H01Q3/30 ,  H04B1/69 ,  H04B7/04 ,  H04B7/08

CPC分类号： G01S7/023 ,  G01S13/288 ,  G01S13/325 ,  G01S2013/0281 ,  H01Q3/26 ,  H01Q3/2605 ,  H01Q3/30 ,  H04B1/69 ,  H04B7/0408 ,  H04B7/086

摘要： A virtual beam system operating in an environment, including a non-compatible receiver, includes a transmitting subsystem and a receiving subsystem. The transmitting subsystem includes an array of transmitting elements and an element position encoded composite signal generator for generating an element position encoded composite signal. The array of transmitting elements is operatively coupled to the signal generator. The transmitting subsystem radiates the element position encoded composite signal via the array of transmitting elements. The receiving subsystem is responsive to the element position encoded composite signal and includes a receiving element and an element position encoded composite signal decoder for decoding the element position encoded composite signal. The receiving element is operatively coupled to the signal decoder. The element position encoded composite signal appears to be radiated as a wide beam, with relatively low directive gain, when received and decoded by the non-compatible receiver. Conversely, the element position encoded composite signal appears to be radiated as a narrow beam, with relatively high directive gain, when received by the receiving element and decoded by the signal decoder of the receiving subsystem.

摘要翻译： 在包括不兼容接收机的环境中操作的虚拟波束系统包括发射子系统和接收子系统。 发射子系统包括发射元件阵列和元件位置编码复合信号发生器，用于产生元件位置编码复合信号。 发射元件的阵列可操作地耦合到信号发生器。 发射子系统经由发射元件阵列辐射元件位置编码复合信号。 接收子系统响应于元件位置编码的复合信号，并且包括接收元件和元素位置编码的复合信号解码器，用于对元件位置编码复合信号进行解码。 接收元件可操作地耦合到信号解码器。 当由不兼容的接收机接收和解码时，元素位置编码的复合信号似乎被辐射为宽波束，具有相对低的指令增益。 相反地​​，元件位置编码的复合信号似乎被辐射为窄波束，具有较高的指令增益，当被接收元件接收并被接收子系统的信号解码器解码时。

公开(公告)号：US5827900A

公开(公告)日：1998-10-27

申请号：US532263

申请日：1995-09-22

申请人： Joseph Levy ,  Yoav Sharoni

发明人： Joseph Levy ,  Yoav Sharoni

IPC分类号： A61K31/01 ,  A61K36/81 ,  A61P35/00

CPC分类号： A61K31/01

摘要： A method of reducing the activity of a cell comprises administering to the cell of a subject in need thereof, directly or systemically, a cell activity-reducing effective amount of lycopene. Pharmaceutical composition are derscribed, for inhibiting the growth of cancer cells, comprising as an active ingredient a cancer cell growth-inhibiting effective amount of lycopene.

摘要翻译： 降低细胞活性的方法包括向有需要的受试者的细胞直接或全身施用减少细胞活性的有效量的番茄红素。 描述了用于抑制癌细胞生长的药物组合物，其包含作为活性成分的癌细胞生长抑制有效量的番茄红素。

公开(公告)号：US4284415A

公开(公告)日：1981-08-18

申请号：US92383

申请日：1979-11-08

申请人： Gary W. Y. Kwong ,  Joseph Levy

发明人： Gary W. Y. Kwong ,  Joseph Levy

IPC分类号： C10L1/22

CPC分类号： C10L1/221

摘要： An additive for inhibiting sedimentation and retarding degradation of hydrocarbon oils as evidenced by discoloration comprises the reaction product of an alkoxyalkylamine with an epihalohydrin at a temperature from about 40.degree. C. to about 150.degree. C. in the presence of an inorganic base.

摘要翻译： 通过变色证明的用于抑制烃油沉降和延迟降解的添加剂包括在无机碱存在下，在约40℃至约150℃的温度下，烷氧基烷基胺与表卤代醇的反应产物。